Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Opioid Supply Be Slashed? US Attorney General Takes Aim At Aggregate Production Quotas

Executive Summary

Looking to reduce opioid prescriptions, Sessions asks DEA to consider revising regulations governing its quotas. President Trump says DOJ may file separate suit against opioid makers.

You may also be interested in...



Opioid Spotlight: Trump Announces Plans For More Spending As Congress Introduces Two Dozen Bills

Administration also plans to roll out slate of proposals to decrease drug prices and bring discounts to patients.

Opioid Litigation: US DOJ Intensifies Pressure On Sponsors With New Task Force

Task force will target unlawful marketing by opioid manufacturers, assist state lawsuits, and seek compensation for costs of opioid crisis.

Standardization Of Patient-Focused Core Clinical Outcomes Could Enable Labeling Comparisons

US FDA’s Theresa Mullin envisions having a national catalog of standard core clinical outcomes assessment measures that could apply to every disease area.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS122633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel